Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment. The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies, which are emerging as groundbreaking and promising cancer treatment strat...

Full description

Saved in:
Bibliographic Details
Published in:Signal transduction and targeted therapy 2020-07, Vol.5 (1), p.137, Article 137
Main Authors: Wang, Qiao, Peng, Hongling, Qi, Xiaorong, Wu, Min, Zhao, Xia
Format: Article
Language:English
Subjects:
631/67/1059/153
631/67/1517
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Cancer Research
Cell Biology
Female
Genital Neoplasms, Female - blood
Genital Neoplasms, Female - drug therapy
Genital Neoplasms, Female - metabolism
Gynecological cancer
Gynecology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Pathology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Review
Review Article
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment. The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies, which are emerging as groundbreaking and promising cancer treatment strategies. In gynecologic malignancies, potential therapeutic targeted agents include antiangiogenic agents, poly (ADP-ribose) polymerase (PARP) inhibitors, tumor-intrinsic signaling pathway inhibitors, selective estrogen receptor downregulators, and immune checkpoint inhibitors. In this article, we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.
ISSN:2059-3635
2095-9907
2059-3635
DOI:10.1038/s41392-020-0199-6